Tevogen Bio Holdings Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ryan H. Saadi
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 15 Independence Blvd Warren NJ United States of America 07059
- IPO Date
- Jan 5, 2022
- CIK
- 0001860871
- Website
- tevogen.com
- Similar Companies
- Business
- Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy company that leverages its proprietary ExacTcell technology platform to harness CD8+ cytotoxic T lymphocytes for developing off-the-shelf, precision T cell therapies targeting infectious diseases, cancers, and neurological disorders; its lead candidate, TVGN 489, has completed Phase 1 trials for high-risk ambulatory COVID-19 patients and is in Phase 1 for acute SARS-CoV-2 in B-cell suppressed patients including those with B-cell cancers as well as Long COVID prevention and treatment; additional pipeline products in preclinical development include TVGN 920 for cervical cancer, TVGN 960 for oropharyngeal cancer, TVGN 601 for multiple sclerosis, TVGN 930 for Epstein-Barr virus-associated lymphomas, and TVGN 116 for hepatitis B. The company, founded in 2020 and headquartered in Warren, New Jersey, focuses on large patient populations across virology, oncology, and neurology segments with an emphasis on affordability and broad accessibility through efficient manufacturing and AI-enhanced drug discovery via Tevogen.AI. Recent developments include receipt of $3 million in non-dilutive grant funding from KRHP LLC since January 2025 toward a potential $10 million total to advance Tevogen.AI for target discovery and development acceleration; expansion of its Warren headquarters facility, fully funded by CEO Ryan Saadi, to centralize R&D, AI, and executive teams; a partnership with Databricks to enhance AI-driven precision immunotherapy; and a $50 million agreement for CD8 technology services to bolster R&D and U.S. manufacturing capabilities.
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen Bio Explores Buyout To Boost Generics Platform
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen Announces Reverse Stock Split
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus